Health Trials

Extravascular Hemolysis

2

Review clinical trials related to Extravascular Hemolysis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Available

Danicopan Early Access Program

This is an EAP, designed to provide early access to danicopan for participants with PNH experiencing clinically significant EVH who have failed, not tolerated, or are unable to receive other approved treatments; in the Treating Physician's opinion, the participant is not eligible for or is not able to participate in an ongoing clinical trial of danicopan or a comparable treatment; and according to the Treating Physician, the benefit of danicopan treatment outweighs the potential risks.

Trial details
Age: 18+Biological sex: AllType: Expanded AccessSponsor: Alexion Pharmaceuticals, Inc.Updated: Jun 4, 2026Locations: 15
Eligibility criteria

Male or female, aged 18 years and older [+5]

Participants who are nursing or pregnant (or women who are planning to become pr... [+4]

Read more
Status: Recruiting

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

The primary objective of this study is to evaluate efficacy of danicopan as add-on treatment to ravulizumab or eculizumab as assessed by hemoglobin (Hgb) change from Baseline at Week 12 in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH) and clinically significant extravascular hemolysis (CS-EVH).

Participants needed: 6
Trial details
Phase: Phase 3Age: 12-17Biological sex: AllType: InterventionalSponsor: Alexion Pharmaceuticals, Inc.Updated: Dec 23, 2025Locations: 4
Eligibility criteria

Confirmed diagnosis of PNH. [+4]

Platelet count < 30000/μL or there is a need for platelet transfusions. [+8]

Read more